The evidence behind the possibilities

Science, in depth.
Discovery, in motion.

Explore published studies, preprints, and conference research from across the nference ecosystem.

100 publications
NeurosciencePeer-Reviewed Journal Publication

Somatosensory and peripheral neuropathic outcomes after semaglutide or tirzepatide initiation compared with other anti-diabetic medications

In this observational study we found no evidence of a population-level excess of documented somatosensory or peripheral neuropathic phenotypes after semaglutide or tirzepatide initiation; the modestly lower incidence was within the range of systematic error indicated by the negative controls.

Biology Methods and Protocols
November 4, 2026
CardiometabolismPreprint - Submitted for Peer-Review

Excessive Weight Loss with Zepbound Is Associated with Higher Rates of Adverse Events, Electrolyte Imbalances, and Hospitalization than Moderate Weight Loss

While residual confounding and documentation differences may contribute to some real-world associations, the significantly greater burden of adverse events, hospitalization rates, laboratory test anomalies, and vital-sign abnormalities among Zepbound patients with excessive weight loss warrants further investigation.

Preprints.org
October 21, 2026
CardiometabolismConference

Menopause Hormone Therapy and Weight Loss Response to GLP-1–Based Therapies in Midlife Women: A Retrospective Cohort Study

In this large real-world cohort of midlife women treated for overweight or obesity, concomitant HT was associated with significantly greater and sustained weight loss with SEM. A similar directional effect with TZP was observed at early timepoints but did not reach statistical significance. Larger prospective studies are warranted to confirm these observations and to inform individualized treatment strategies in midlife women.

The Menopause Society — 2026 Annual Meeting
October 20, 2026
CardiometabolismPreprint - Submitted for Peer-Review

Weight Regain During Continued Incretin Therapy Is Associated With an Inflammatory Signature at Weight Nadir and Higher Cardiovascular Event Rates

Among 58,618 semaglutide or tirzepatide initiators who lost at least 5% of body weight, 14.3% regained at least five percentage points by one year. Regain sometimes occurred despite continued treatment documentation and coincided with inflammatory signals and higher cardiovascular event rates, but medication use and causality could not be confirmed.

Preprints.org
August 21, 2026
Ideas are connected. Your next discovery starts here.